BeAT-HF Trial

SUPERIORITY

Barostim BAT + OMT demonstrated superiority vs OMT alone in a multi-center, prospective, randomized controlled trial

SYMPTOMATIC IMPROVEMENTS

BAT demonstrated significant and meaningful symptomatic improvements in NYHA class, 6MHW and QOL

SAFE PROCEDURES

BAT was associated with 97% MANCE-free survival and a 51% reduction in serious cardiovascular events

REDUCTIONS IN
NT-proBNP

BAT produced significant and clinically meaningful reductions in NT-proBNP

Barostim BAT Achieves Significant and Meaningful Improvements in Heart Failure Symptoms

60m

greater 6MHW results with BAT

34%

more improved at least 1 NYHA class at 6 months (p<0.001)

14point

improvement in QOL with BAT

Significant Reduction in NT-ProBNP and Collection of Morbidity and Mortality Data

25%

reduction in NT-proBNP with Barostim

1. Zile MR, Abraham WT, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction, J Am Coll Cardiol 2020; 76:1-13 

Safe Procedures and a Potential Reduction in Serious Cardiovascular Events

97%

MANCE-Free Survival in BAT arm

51%

*Potential Reduction in Serious Cardiovascular Events with BAT

* https://www.cvrx.com/beat-hf-presented-at-esc-hf/ 

Learn About Barostim Reimbursement

Reimbursement
circles